Fantofarone
CAS: 114432-13-2
Ref. 3D-PEA43213
1mg | Descontinuado | ||
5mg | Descontinuado | ||
10mg | Descontinuado | ||
25mg | Descontinuado | ||
50mg | Descontinuado |
Informação sobre produto
- 1-((p-(3-((3,4-Dimethoxyphenethyl)methylamino)propoxy)phenyl)sulfonyl)-2-isopropylindolizine
- 3,4-Dimethoxy-N-methyl-N-(3-(4-((2-(1-methylethyl)-1-indolizinyl)sulfonyl)phenoxy)propyl)benzeneethanmine
- 3,4-Dimethoxy-N-methyl-N-[3-[4-[[2-(1-methylethyl)-1-indolizinyl]sulfonyl]phenoxy]propyl]benzeneethanamine
- Benzeneethanamine, 3,4-dimethoxy-N-methyl-N-(3-(4-((2-(1-methylethyl)-1-indolizinyl)sulfonyl)phenoxy)propyl)-
- Fantofarona
- Fantofarona [INN-Spanish]
- Fantofarone [INN:BAN]
- Fantofaronum
- Fantofaronum [INN-Latin]
- N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methyl-3-(4-{[2-(propan-2-yl)indolizin-1-yl]sulfonyl}phenoxy)propan-1-amine
- Ver mais sinónimos
- Sr 33557
- Unii-Ku213Xyo69
Fantofarone is a calcium channel blocker that binds to the α1 subunit of the L-type calcium channel. It inhibits the release of neurotransmitters such as glutamate, which are associated with pain and other neurological symptoms. Fantofarone has not been shown to cause any cardiac side effects, but it has been shown to lower diastolic pressure and increase atrial and systolic pressure in some patients. The drug has been shown to decrease cerebellar Purkinje neurons in animal studies, but this effect has not been seen in humans. Fantofarone also blocks the release of neurotransmitters such as glutamate, which are associated with pain and other neurological symptoms.